Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

1.312 -9.628 (-88.01%)
Streaming Delayed Price Updated: 9:49 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 6 Next >
News headline image
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Rezolute ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Rezolute ↗
 
Via Benzinga
News headline image
Short Volatility Alert: Rezolute, Inc. ↗
On Tuesday, shares of Rezolute, Inc. (NASDAQ: RZLT) experienced volatile short activity. After the activity, the stock price went down -2.59% to $3.01. The overall sentiment for RZLT has been Bearish. 
Via Benzinga
News headline image
Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
News headline image
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rezolute to Participate in Upcoming Investor Conferences in September
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare... 
Via Newsfile
News headline image
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
From Rezolute, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
News headline image
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Present at the Jefferies London Healthcare Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 111 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
News headline image
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 41 companies made new 52-week lows. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.